The Novartis 2020 Revenue was around 48 Billion US$.
R & D expenditure around 9 Billion US$ and has been relatively steady at this level for the past 7 years (some room to increase I suspect).
Our ARDS project could easily be amortized into these numbers.
Time is fleeting.
Not too long to go before we learn if Novartis will embrace the msb ARDS opportunity.
Keep Calm and be Kind,
What.
Disclosure issues, page-99
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |